Edition:
United Kingdom

Affimed NV (AFMD.OQ)

AFMD.OQ on NASDAQ Stock Exchange Global Market

3.86USD
7:54pm GMT
Change (% chg)

$0.09 (+2.39%)
Prev Close
$3.77
Open
$3.85
Day's High
$4.05
Day's Low
$3.76
Volume
146,990
Avg. Vol
249,664
52-wk High
$7.35
52-wk Low
$1.17

Chart for

About

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its... (more)

Overall

Beta: --
Market Cap(Mil.): $96.98
Shares Outstanding(Mil.): 43.26
Dividend: --
Yield (%): --

Financials

  AFMD.OQ Industry Sector
P/E (TTM): -- 85.49 33.64
EPS (TTM): -0.99 -- --
ROI: -62.77 -0.29 14.22
ROE: -67.79 0.40 15.99

Affimed puts on hold cancer drug trial after patient death

Oct 8 Drug developer Affimed N.V. on Monday put on hold the testing of its experimental cancer drug following the death of a patient and two life-threatening events.

08 Oct 2018

BRIEF-Affimed To Collaborate With Genentech To Develop Novel Nk Cell Engager-Based Immunotherapeutics

* AFFIMED ANNOUNCES COLLABORATION WITH GENENTECH TO DEVELOP NOVEL NK CELL ENGAGER-BASED IMMUNOTHERAPEUTICS FOR MULTIPLE CANCER TARGETS

27 Aug 2018

Earnings vs. Estimates